Short answer
Apogee Therapeutics, Inc. (APGE) filed an 8-K current report with the SEC on August 10, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Quarterly results for period ended June 30, 2026, covering Apogee’s business update and financial performance.
Apogee Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Quarterly results for period ended June 30, 2026, covering Apogee’s business update and financial performance
- Earnings Press Release furnished as Exhibit 99.1, containing the substantive operating and financial details
Item EX-99.1 · Exhibit EX-99.1
- Pending AbbVie acquisition at $135.11 per share cash, valuing Apogee’s equity at approximately $10.9 billion
- Transaction expected to close in Q3 2026, subject to shareholder and regulatory approvals
- Zumilokibart Phase 2 achieved 65.9% EASI-75 response and 41.9% placebo-adjusted response, supporting Phase 3 launch this year
- Cash, marketable securities and long-term securities reached $1.3 billion at June 30, 2026, versus $621.2 million one year earlier
- Q2 net loss widened to $85.9 million from $66.1 million as R&D increased to $67.3 million and G&A to $24.3 million
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Apogee Therapeutics, Inc. 8-K filings
Get the next APGE 8-K as it lands
Follow APGE for push alerts, or ask the research agent what this filing means.